A decision is anticipated in the coming weeks. If approved, Eylea 8 mg would become the only anti-VEGF therapy in the EU offering treatment intervals of up to six months for both nAMD and DME.

Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label extension for Eylea 8 mg ...

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of neovascular (wet) age-related macular ...

The company’s product portfolio is anchored by Eylea, used in treating various eye diseases, and Dupixent, which has shown significant growth potential across multiple indications. In the first ...

CEO Leonard Schleifer specifically cited a funding gap at patient assistance foundations as a catalyst for more patients and physicians turning to off-label Avastin over EYLEA, resulting in a ...

Bayer A.G. (OTCPK:BAYZF) (OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the label expansion of a high-dose version of its ophthalmic drug, Eylea ...

Columbia University has temporarily suspended 65 students after anti-Israel agitators took over a campus building and handed out pamphlets that glorified an alleged terrorist this week.

This case[1] involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions of EYLEA®, a drug used to treat eye diseases ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

A brochure shared on Reddit provides new details on Eufy’s first smart display. According to the brochure, the Smart Display E10 features an eight-inch touchscreen with an HD resolution.